Short Interest in Mylan N.V. (MYL) Rises By 17.0%
Mylan N.V. (NASDAQ:MYL) was the recipient of a significant growth in short interest in September. As of September 15th, there was short interest totalling 26,525,497 shares, a growth of 17.0% from the August 31st total of 22,672,282 shares. Approximately 5.2% of the company’s stock are short sold. Based on an average trading volume of 6,722,873 shares, the short-interest ratio is currently 3.9 days.
Institutional investors have recently bought and sold shares of the business. Global X Management Co. LLC grew its holdings in shares of Mylan N.V. by 91.6% during the first quarter. Global X Management Co. LLC now owns 3,015 shares of the company’s stock worth $118,000 after purchasing an additional 1,441 shares during the last quarter. TLP Group LLC acquired a new position in Mylan N.V. during the 1st quarter worth about $200,000. Doliver Capital Advisors LP acquired a new position in Mylan N.V. during the 2nd quarter worth about $201,000. Eagle Global Advisors LLC acquired a new position in Mylan N.V. during the 2nd quarter worth about $205,000. Finally, Sheaff Brock Investment Advisors LLC acquired a new position in Mylan N.V. during the 2nd quarter worth about $210,000. 71.97% of the stock is currently owned by institutional investors.
Shares of Mylan N.V. (NASDAQ:MYL) opened at 32.39 on Tuesday. The firm has a market cap of $17.37 billion, a PE ratio of 26.18 and a beta of 1.30. Mylan N.V. has a 12-month low of $29.39 and a 12-month high of $45.87. The company has a 50 day moving average of $31.35 and a 200-day moving average of $36.53.
Mylan N.V. (NASDAQ:MYL) last released its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 EPS for the quarter, missing the Zacks’ consensus estimate of $1.18 by ($0.08). The business had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $3 billion. Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. During the same quarter last year, the company earned $1.16 earnings per share. The firm’s revenue was up 15.7% on a year-over-year basis. Equities research analysts forecast that Mylan N.V. will post $4.52 EPS for the current fiscal year.
MYL has been the subject of several recent analyst reports. Cowen and Company reissued a “hold” rating and set a $30.00 price objective (down from $43.00) on shares of Mylan N.V. in a report on Wednesday, August 9th. Wells Fargo & Company set a $30.00 target price on shares of Mylan N.V. and gave the company a “hold” rating in a research note on Wednesday, August 9th. Cantor Fitzgerald set a $34.00 target price on shares of Mylan N.V. and gave the company a “hold” rating in a research note on Wednesday, August 9th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $32.00 price target (down previously from $33.00) on shares of Mylan N.V. in a research report on Thursday, August 10th. Finally, ValuEngine raised shares of Mylan N.V. from a “hold” rating to a “buy” rating in a research report on Monday. Two research analysts have rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Mylan N.V. has an average rating of “Buy” and an average target price of $42.46.
About Mylan N.V.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Stock Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related stocks with our FREE daily email newsletter.